AKR1C3 and acute lymphoblastic leukemia: All three enzymes have been reported to play a role in chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL)10, and a pan-AKR1C inhibitor outperformed the AKR1C3 selective inhibitor medroxyprogesterone acetate in reducing cell viability in several acute myeloid leukemia (AML) cell lines.